MedTrace Logo

A Post-Marketing Observational Study of VYXEOS™

NCT03526926 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 52

Last updated 2020-08-05

No results posted yet for this study

Summary

The purpose of this observational study is to provide data on the incidence and severity of infusion-related reactions during and immediately following each infusion of VYXEOS during the first induction.

Conditions

  • Acute Myeloid Leukemia With Myelodysplasia-Related Changes
  • Therapy-Related Acute Myeloid Leukemia

Interventions

DRUG

CPX-351

VYXEOS is administered as an intravenous (IV) infusion over approximately 90 minutes.

Sponsors & Collaborators

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-10-23
Primary Completion
2019-10-26
Completion
2020-06-12
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03526926 on ClinicalTrials.gov